Randomised Double-blind Placebo Controlled Trial of Topical Autologous Platelet Lysate in Venous Ulcer Healing

Stacey, Michael; Matà, Sabrina; Trengove, Naomi; Mather, Carey

doi:10.1053/ejvs.2000.1134

Cited by 91 publications

(107 citation statements)

References 21 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…For example, Stacey and colleagues reported that topical application of platelet lysates on the ulcers did not influence the healing [44]. The application of a fibrin scaffold-like PRGF, in which rapid clearance of growth factors and proteins is prevented, might shed light on this controversy.…”

Section: Article In Pressmentioning

confidence: 99%

The potential impact of the preparation rich in growth factors (PRGF) in different medical fields☆

et al. 2007

View full text Add to dashboard Cite

Section: Article In Pressmentioning

confidence: 99%

The potential impact of the preparation rich in growth factors (PRGF) in different medical fields☆

et al. 2007

View full text Add to dashboard Cite

“…Another study evaluated 86 patients with venous ulcers randomized to treatment with autologous platelet lysate versus placebo and compression, but no difference was achieved in time to ulcer healing for platelet lysate compared with the placebo. 45 A promising study using recombinant FGF (Repifermin; Human Genome Sciences, Inc., Rockville, Md.) evaluated 94 patients with venous ulcers.…”

Section: Growth Factorsmentioning

confidence: 99%

Venous Ulcer: What Is New?

Raffetto

Marston

2011

Plastic and Reconstructive Surgery

View full text Add to dashboard Cite

The pathophysiology of venous dermal abnormality in chronic venous ulcers is reflective of a complex interplay that involves sustained venous hypertension, inflammation, changes in the microcirculation, cytokine and matrix metalloproteinase activation, and altered cellular function. Red blood cells and macromolecules extravasate into the interstitium and activate endothelial cells. Endothelial expression of specific adhesion molecules recruits leukocytes and causes diapedesis of these cells into the dermal microvasculature, promoting an inflammatory response with activation of cytokines and proteinases. Altered cell function enhances a state of vulnerability in the surrounding tissues, initiating specific changes associated with venous disease. Ultimately, the persistent inflammatory-proteinase activity leads to advanced chronic venous insufficiency and ulcer formation. The mainstay of therapy in venous ulcer abnormality is correction of the underlying venous hypertension through compression therapy and/or surgery. Understanding the science involved in the pathophysiology of venous ulcer formation has led to the development of adjunctive treatment directed at the dysregulated molecular pathways. Randomized clinical trials are critical for determining the most effective evidence-based treatments for venous ulcer, and this review discusses important trials that have had a significant impact on venous ulcer healing. In addition, the authors have included subsections referred to as "Translational Implications for Therapy" in the basic science sections of the review to help bridge the basic science knowledge with clinical applications that may help to modulate the molecular abnormalities in the pathophysiologic cascade leading to venous ulcers.

show abstract

“…Thirteen randomized clinical trials 25,[32][33][34][35][36][37][38][39][40][41][42][43][44] were also included in this review, six of which were double-blind placebo-controlled trials 25,[32][33][34][35][36] (Table 2). Regarding etiology, five of the studies recruited mixed-etiology ulcers, 25,32,36,38,41 three considered venous ulcers, 33,34,42 and the other five diabetic foot ulcers.…”

mentioning

confidence: 99%

“…Regarding etiology, five of the studies recruited mixed-etiology ulcers, 25,32,36,38,41 three considered venous ulcers, 33,34,42 and the other five diabetic foot ulcers. 36,37,39,40,44 Four studies, including mixed ulcers and venous ulcers, did not find clinical evidence to support the benefit of PRP in wound healing.…”

mentioning

confidence: 99%

“…36,37,39,40,44 Four studies, including mixed ulcers and venous ulcers, did not find clinical evidence to support the benefit of PRP in wound healing. [32][33][34][35] The largest study considering just venous ulcers was conducted by Stacey et al, 33 and included 86 patients (42 in the experimental and 44 in the control group). Autologous platelets were separated by centrifugation and platelet lysate was obtained by sonication.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Platelet-rich plasma for the treatment of chronic wounds: evidence to date

Conde-Montero¹,

Dobao²,

González³

2017

CWCMR

View full text Add to dashboard Cite

Platelet-rich plasma (PRP) is a widely used throughout diverse fields of medicine for improving tissue regeneration. In dermatology, its main applications in the last few years have mainly been in antiaging treatment and wound healing. PRP contains platelets at higher concentrations than whole blood, and consequently represents a growth-factor pool. Chronic wounds are characterized by a prolonged inflammatory phase, involving a continuous destruction of matrix proteins and growth factors. Growth factors promote cell migration, proliferation, and differentiation, which are essential for wound healing. In this review, we explain the basic principles of PRP in wound healing and aim to offer an updated critical assessment of the available clinical evidence that supports the utility of PRP for the therapeutic challenge that chronic ulcers represent in our daily clinical practice.

show abstract

Randomised Double-blind Placebo Controlled Trial of Topical Autologous Platelet Lysate in Venous Ulcer Healing

Abstract: platelet lysate prepared and delivered by the method used in this study had no influence on the healing of chronic venous ulceration.

Cited by 91 publications

References 21 publications

The potential impact of the preparation rich in growth factors (PRGF) in different medical fields☆

The potential impact of the preparation rich in growth factors (PRGF) in different medical fields☆

Venous Ulcer: What Is New?

Platelet-rich plasma for the treatment of chronic wounds: evidence to date

Contact Info

Product

Resources

About